Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

146.64 +1.37 (+0.94%)
Official Closing Price Updated: 4:10 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,462,462
Open 145.44
Bid (Size) 146.42 (1)
Ask (Size) 146.64 (10)
Prev. Close 145.27
Today's Range 144.81 - 147.91
52wk Range 140.68 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?
Via The Motley Fool
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments. 
Via Benzinga

Performance

YTD
+1.82%
+1.82%
1 Month
+0.94%
+0.94%
3 Month
-11.59%
-11.59%
6 Month
-6.17%
-6.17%
1 Year
-8.24%
-8.24%

More News

Read More
Where Johnson & Johnson Stands With Analysts
Via Benzinga
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find
Via The Motley Fool
Earnings Picture Remains Strong: A Closer Look
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
Via Benzinga
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Johnson & Johnson Q4 Earnings And Revenues Top Estimates
Via Talk Markets
Topics Stocks / Equities
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient
Via Stocktwits
Topics Earnings
Exposures Financial
Johnson & Johnson Tops Q4 EPS Forecasts
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Via Benzinga
Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
From Johnson & Johnson
Via Business Wire
US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch
Via Benzinga
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Earnings Scheduled For January 22, 2025
Via Benzinga
Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF
Via Talk Markets
Topics Government Stocks / Equities
Exposures Political
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Via Benzinga
Exposures Product Safety
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
Via Benzinga
Exposures Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.